Isradipine
From Wikipedia, the free encyclopedia
Isradipine
|
|
Systematic (IUPAC) name | |
methyl propan-2-yl 2,6-dimethyl-4- (8-oxa-7,9-diazabicyclo[4.3.0] nona- 2,4,6,9- tetraen- 5-yl)- 1,4-dihydropyridine- 3,5-dicarboxylate | |
Identifiers | |
CAS number | |
ATC code | C08 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C19H21N3O5 |
Mol. mass | 371.387 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 95% |
Metabolism | ? |
Half life | 8 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Isradipine (tradenames DynaCirc, Prescal) is a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack. More recent research suggests that isradipine may have potential uses for treating Parkinson's disease (Chan et al, 2007).
[edit] Further reading
- Hattori T, Wang P (2006). "Calcium antagonist isradipine-induced calcium influx through nonselective cation channels in human gingival fibroblasts.". Eur J Med Res 11 (3): 93–6. PMID 16751108.
- Ganz M, Mokabberi R, Sica D (2005). "Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study.". J Clin Hypertens (Greenwich) 7 (4 Suppl 1): 27–31. doi: . PMID 15858400.
- Johnson B, Roache J, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y (2005). "Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects.". Int J Neuropsychopharmacol 8 (2): 203–13. doi: . PMID 15850499.
- Fletcher H, Roberts G, Mullings A, Forrester T (1999). "An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia.". J Obstet Gynaecol 19 (3): 235–8. doi: . PMID 15512286.
[edit] External links
- MedlinePlus DrugInfo medmaster-a693048
- DDB 30003
- Drug offers hope for Parkinson's - BBC News, 11 June 2007.
|